(MOL.F)
| Previous close | 6.1500 |
| Open | N/A |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | N/A - N/A |
| 52-week range | 3.9900 - 12.7500 |
| Volume | |
| Avg. volume | 21 |
| Market cap | 0 |
| Beta (5Y monthly) | 1.85 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 09 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireMoleculin to Host Virtual AML Clinical Day Featuring Internationally Renowned Clinician, Martin S. Tallman, MD, on May 7, 2024
Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that it will host a virtual AML Clinical Day on Tuesday, May 7, 2024 at 11:00 AM ET.
PR NewswireMoleculin Announces Formation of Scientific Advisory Board to Support Development of Annamycin
Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced the formation of its Annamycin Scientific Advisory Board and inaugural appointment of Dr. Martin Tallman.
PR NewswireEuropean Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)
Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to Annamycin for the treatment of AML.
